Varicose Veins — Trunk Choice by CLASS Arithmetic, the ESCHAR-EVRA Ulcer Split, Tributary Timing, and the Non-Thermal Durability Discount

A 34-year-old woman with aching great saphenous varices after two pregnancies, a 68-year-old man with a healed venous ulcer and isolated superficial reflux, and a 71-year-old woman with an active ulcer and a refluxing trunk. One needs trunk-choice counselling with CLASS numbers, one needs the ESCHAR recurrence conversation, and one needs EVRA-timed early ablation with compression. The examiner will watch you speak CEAP-2020, define reflux by the duplex rule, separate healing from recurrence, price foam and mechanochemical options by their long-term reintervention rates, and consent nerve, thrombus-extension and recurrence risk — with every number taken from the papers named beside it.^{[6][3][9][12][36]}

Overview & Definition — reflux first, skin changes later, ulcers last

Primary varicose veins are the visible, reflux-driven stage of chronic venous disease: valvular incompetence produces superficial reflux, reflux sustains venous hypertension, and hypertension climbs from trunk varices through oedema and skin change to ulceration.^[1][3] The population burden is large: trunk varices affect around one-third of women, open ulcers affect about 0.3% of adults, and around 1% carry an open-or-healed ulcer history — with ulceration risk tracking varicosity severity and rising after deep vein thrombosis.^[1] Edinburgh reframes the sex assumption: in 1566 subjects from 12 practices, age-adjusted prevalence ran higher in men than women (39.7 versus 32.2%) with a male odds ratio of 2.11 after lifestyle adjustment — so the current study casts doubt as to whether varicose veins occur predominantly in women.^[2] The strategic arc fits one sentence: define reflux by duplex, stage by CEAP, ablate the trunk by CLASS arithmetic, time tributaries concomitantly, reserve surgery-plus-compression for ulcer recurrence and early ablation for ulcer healing, and keep compression on every healed leg.^{[3][6][26][9][12][34]}

Classification — CEAP-2020 language with two meters beside it

CEAP is the internationally accepted standard for describing chronic venous disorders, born in 1993, updated in 1996 and revised in 2004; the 2020 update adds corona phlebectatica as the C4c subclass, introduces the modifier "r" for recurrent varicose veins and recurrent venous ulcers, and replaces numeric venous-segment descriptions with their common abbreviations.^[6] Bonn shows why subscripts matter: in 3072 participants, age, pregnancies, family history and overweight are shared across varicose veins, C3 oedema and severe C4–C6 disease — but female gender is significantly associated with varicose veins and C3 and not with severe C4–C6 disease, so counsel the bulge and the skin change with different risk stories.^[5] Meter the disease with two instruments: in 100 chronic-venous-insufficiency patients treated by laser or foam, median VCSS falls from 6 to 2 and AVVQ from 21.4 to 8.8 at 3 months, with the first three VCSS questions — pain, extent of varicosities, oedema — contributing most to the overall score.^[7]

Each classification answers a different viva question — CEAP stages what you see, VCSS grades what the patient feels, and AVVQ prices what treatment buys.^[6][7]

Populations & Denominators — the trial counts that frame every decision

The population cohorts run Edinburgh 1566 at baseline with 880 re-examined at 13 years, and Bonn 3072 with a 59% response proportion.^[3][5] The ulcer founders randomise ESCHAR 500 legs across three UK centres and EVRA 450 patients across 20 UK centres, with 6105 screened out for ulcer duration, healed status, deep occlusion or insufficient reflux.^[9][13] The trunk-choice trials contribute CLASS 798, the Dutch 3-arm 240, REACTIV 1009, Cochrane 13 trials with 3081 patients, Carradice 280, Darwood three arms, Pronk 130 legs, Flessenkämper 449, LAMA 150, the Helsinki mechanochemical-thermal cohort 125, the 14-year cohort 233 randomised with 214 analysed, VenaSeal Spectrum 106 plus 275, and the glue trial 177.^{[15][17][18][19][20][21][22][24][27][28][29][30][31]} The series and consensus add Marston 173 C5/C6 limbs, Chan glue-ulcer 37 patients, compression Cochrane 8 trials with 1995 participants, the systems network 21 trials with 2934 participants, flush-EVLA 405 limbs, VTE consensus 42 then 47 consultants, SSV anatomy 20 specimens, recanalisation pooling 1226 legs, and RFA-cost 156 limbs.^{[32][33][34][35][36][37][38][39][40]}

Clinical Presentation — ache, tributaries, oedema, skin, ulcer

The uncomplicated trunk declares through ache, heaviness and visible tributaries in C2 disease, varying with pregnancies and family history — the shared Bonn risk factors of age, pregnancies, family history and overweight — with prolonged standing only a bias-prone suggestion, never an established cause.^[5][1] Oedema marks C3, corona and skin change mark C4, healed ulceration marks C5 and the open ulcer marks C6 — with nearly one-third of varicose-vein-only patients developing chronic venous insufficiency over 13 years and almost all combined disease deteriorating.^[4] The ulcer declares through gaiter-zone breakdown over refluxing superficial trunks, sometimes with coexistent deep reflux — present in nearly one-third of Marston endovenous limbs — and recurrence declares through the same gaiter zone after healing, striking over half of compression-only legs at 4 years.^[32][10] Recurrence after trunk treatment declares through groin duplex first and symptoms second: at 10 years duplex freedom runs 73% after stripping against 44% after 980-nm bare-fibre laser, with clinical freedom at 77 versus 58%.^[23]

Differential Diagnosis — reflux versus obstruction, superficial versus deep, venous versus the rest

Split reflux from obstruction first: duplex reflux at 0.5 seconds or longer defines the reflux population, while deep occlusive disease diverts to a different pathway — EVRA excluded deep venous occlusive disease among its 6105 screen failures.^[3][13] Split isolated superficial reflux from combined deep-and-superficial disease before promising results: baseline combined reflux multiplies new varicose veins 7.3-fold against 4.4-fold for isolated superficial, and ESCHAR total-deep reflux erases the recurrence advantage (46 vs 32%, P=0.33) that holds in isolated and segmental disease.^[3][10] Split primary varices from the secondary mimics — post-thrombotic limbs carry the deep-reflux penalty, overweight doubles reflux risk, and prior deep thrombosis multiplies it eleven-fold — so name the driver before booking the trunk.^[3] Confirm venous aetiology with duplex of the ulcerated or recently healed leg before any ablation conversation — ESCHAR imaged 500 consecutive legs this way — and never ablate a leg whose deep system is occluded.^[9][13]

Name the reflux pattern aloud before ordering treatment — the viva rewards the candidate who separates what the trunk decides from what only depth, diameter or timing decides.^[3][39]

Clinical & Bedside Assessment — trunk, tributaries, skin, pulses, risk

Map the trunk and its tributaries standing: which saphenous system refluxes, how many segments, what diameter — because clinical class (OR 2.1) and diameter (OR 1.8) are the strongest predictors of 1-year recanalisation across 1226 thermally ablated legs.^[39] Stage the skin precisely — C2 tributaries, C3 oedema, C4 skin change including C4c corona, C5 healed, C6 open — and record VCSS and AVVQ at baseline so the 6-to-2 and 21.4-to-8.8 improvements mean something at follow-up.^[6][7] Feel pulses and exclude deep occlusion in every ulcer leg: EVRA excluded deep venous occlusive disease among its 6105 screen failures, and ablation treats reflux, never ischaemia.^[13] Count venous-thromboembolism risk factors explicitly: prior thrombosis, and the seven surveyed factors behind the low-molecular-weight-heparin consensus, decide pharmacoprophylaxis — with high-risk patients earning one to two weeks rather than a single dose.^[37] Examine and document nerves before any small saphenous work: the sural nerve lies within 5 mm in 70% of proximal and 90% of distal legs, so the consent and the thermal plan start at the anatomy.^[38]

Investigations — duplex by the 0.5-second rule, diameters for prognosis

Define reflux the Edinburgh way: duplex scanning of deep and superficial systems measuring venous reflux at 0.5 seconds or longer, with the 13-year data showing superficial-only disease in two-thirds of new reflux and the lower-thigh great saphenous segment the single hottest site at 8.1%.^[3] Report the single-centre discriminators with their honesty label: in 792 limbs, diseased great saphenous trunks average 5.68 against 4.00 mm, peak reflux velocity 77.38 against 7.95 cm/s with a 27.4 cm/s cutoff, and reflux time 406.58 against 67.28 ms with a 250 ms cutoff — discriminators from one hospital cohort, never universal thresholds.^[8] Measure diameter for prognosis, not just diagnosis: each step up in trunk diameter multiplies 1-year recanalisation odds 1.8-fold, and the phlebectomy-alone data show small above-tributary diameters predict restored trunk competence.^[39][25] Confirm ulcer aetiology with duplex of the ulcerated or recently healed leg — ESCHAR imaged 500 consecutive legs this way — and stratify deep reflux as none, segmental or total before quoting any recurrence benefit.^[9][11]

Management — Ulcer: ESCHAR prevents recurrence, EVRA accelerates healing

Give ESCHAR-2004 exactly: 500 legs with isolated or mixed reflux randomised to weekly multilayer bandaging (then class-2 stockings) with or without superficial surgery — 24-week healing tied at 65 versus 65%, but 12-month recurrence more than halved at 12 versus 28% with minimal, equal adverse events.^[9] Give the 4-year arc exactly: healing still tied at 89 versus 93%, recurrence 56 versus 31% overall, 51 versus 27% in isolated superficial disease, 52 versus 24% with segmental deep reflux, and a tied 46 versus 32% where total deep reflux dominates — with ulcer-free time at 78 versus 71%.^[10] Give the mechanism exactly: in 214 legs, surgery abolished segmental deep reflux in 10 of 22 and total deep reflux in 3 of 17, lifting median refill time from 10 to 15 seconds — haemodynamic benefit despite coexistent deep disease, with residual saphenous reflux common.^[11] Give EVRA exactly: 450 patients at 20 centres, ablation within 2 weeks of randomisation versus deferred to healing or 6 months — healing hazard 1.38, median 56 against 82 days, 24-week healing 85.6 against 76.3%, ulcer-free time 306 against 278 days, with pain and deep-vein thrombosis the procedural complications.^[12] Give EVRA long-term exactly: among 426 healed legs, 28.4% recurred; time-to-first-recurrence tied (HR 0.82) but the recurrence rate fell to 0.11 against 0.16 per person-year, with early ablation 91.6% likely cost-effective at £20 000 per quality-adjusted life-year over 3 years.^[13]

The resolution is the viva sentence: surgery added to compression buys recurrence and ulcer-free time without hastening healing, while early endovenous ablation buys faster healing and more ulcer-free days — different eras, different modalities, different promises.^[9][10][12]

Management — Trunk: CLASS, Dutch, REACTIV, Cochrane

Give CLASS exactly: 798 patients across 11 UK centres (foam 292, surgery 294, laser 212) — foam gains less AVVQ than surgery at 6 months (-1.74) but matches laser; procedural complications run 1% laser against 7% foam and 8% surgery; truncal ablation favours surgery and laser equally over foam; foam and laser return patients to behaviours faster.^[15] Give CLASS cost exactly: at 6 months foam and laser save £655 and £160 against surgery, and over 5 years laser costs £3640 per quality-adjusted life-year against foam with a 78.7% probability of cost-effectiveness at £20 000 — laser the treatment of choice for suitable patients.^[16] Give the Dutch 3-arm exactly: 240 patients with great saphenous reflux — 1-year anatomic success 88.5% laser, 88.2% surgery, 72.2% foam — with complications low and equal and 84.3% improving a CEAP-C class.^[17] Give REACTIV exactly: 1009 recruited across three severity groups, only the severe group (surgery versus conservative) powered — surgery wins quality of life, symptoms, anatomy and satisfaction, with cost-effectiveness at £7175 per quality-adjusted life-year over 2 years.^[18] Give Cochrane exactly: 13 trials with 3081 patients — laser-versus-surgery recurrence tied by clinician and symptom counts, while laser halves neovascularisation (OR 0.05) and technical failure (OR 0.29); foam-versus-surgery symptomatic recurrence tied with late recanalisation favouring surgery.^[19]

Management — Laser versus surgery head-to-head with long-term honesty

Give Carradice exactly: 280 patients with isolated saphenofemoral incompetence — VCSS, AVVQ and quality-adjusted life-years improve in both arms, but surgery depresses five SF-36 domains early while laser preserves periprocedural quality of life, so surgical patients return to work at 14 against 4 days.^[20] Give Darwood exactly: reflux abolished in 41 of 42 and 26 of 29 laser legs against 28 of 32 surgical legs with tied symptom-score gains — and return to activity at 2 against 7 days, work at 4 against 17 days.^[21] Give Pronk exactly: 130 legs under tumescent anaesthesia — 1-year duplex recurrence tied at 9 versus 10% — with the honesty that laser caused more pain and restricted mobility, self-care and daily activity through the second week.^[22] Give the 10-year honesty exactly: the same cohort at a decade shows duplex groin-recurrence freedom of 73 versus 44% favouring stripping and clinical freedom of 77 versus 58%, with reinterventions at 17 versus 36% — no clear long-term advantage for 980-nm bare-fibre laser over stripping.^[23] Give Flessenkämper exactly: 449 patients in three arms to 6 years — clinical recurrence tied across stripping, laser, and laser-plus-ligation, but most great saphenous reflux and refluxing side branches appear after laser alone while junction-independent recurrences follow stripping.^[24]

The choosing resolution: laser and surgery tie at 1 year on occlusion and symptoms with laser kinder early, stripping holds the 10-year groin, and the 6-year mechanism split explains why — quote the horizon beside every recommendation.^[17][23][24]

Management — Tributaries: select phlebectomy-alone, default concomitant

Give phlebectomy-alone exactly: in 94 patients with thigh-level great saphenous plus tributary incompetence, tributary phlebectomy alone abolished great saphenous reflux in 50% at 1 year with significant diameter fall, freed 66% from symptoms, and left 15 of 47 persisting-but-asymptomatic patients untreated — with a positive reflux-elimination test carrying over 65% success odds alongside low CEAP class, few refluxing segments and small above-tributary diameter.^[25] Give the concomitant verdict exactly: across 6 randomised trials with 432 patients, adding immediate phlebectomy or foam to truncal ablation cuts reintervention to one-third (RR 0.33) with better 6-week AVVQ and 12-month VCSS and no excess of thrombophlebitis, nerve events, pain or serious harm.^[26] The timing resolution: combine by default for the reintervention dividend, stage only where the elimination test and limited disease promise trunk rescue without a second procedure.^[25][26]

Management — Non-thermal: price the durability discount honestly

Give LAMA 5-year exactly: 150 patients with isolated truncal incompetence — anatomic occlusion 91 versus 47% favouring laser over mechanochemical ablation, reintervention 8 versus 21%, with quality of life tied only after the extra procedures.^[27] Give the 7-year exactly: 125 treated with 71.2% seen — proximal reflux in 23% after mechanochemical against 7% after thermal ablation, with reoperations only on the mechanochemical side between years 3 and 7.^[28] Give the 14-year exactly: foam carries 11.7-fold reflux risk against stripping and 5.0-fold against laser (30.8 vs 2.6 vs 6.1%) with reinterventions at 56.4 versus 13.2 versus 8.2% — while quality of life stays tied across all three.^[29] Give VenaSeal Spectrum exactly: 106 patients against stripping and 275 against thermal ablation across 23 centres on four continents — peri-procedural satisfaction 29.3 versus 25.0 favouring glue over stripping, post-procedure satisfaction and reflux-treated proportions comparable to thermal, with mild self-limiting hypersensitivity the signature glue event.^[30] Give the glue randomised trial exactly: 177 patients — 3-month closure non-inferior to radiofrequency at the −10% margin (−0.03%, CI −3.19%) with 12-month closure 7.04% ahead, at the price of longer procedure time.^[31]

Management — Compression: systems heal alike, stockings prevent apart

Give the systems network exactly: 21 trials with 2934 participants — healing hazard ratios cluster near unity (short-stretch 0.972, two-layer 1.044, wraps 0.927 against four-layer-or-hosiery) with four-layer-or-hosiery emerging cost-effective — so choose the system the leg tolerates, since no wrap heals meaningfully faster.^[35] Give Cochrane recurrence exactly: 8 trials with 1995 participants — European class-3 stockings halve reulceration against none (RR 0.46, low certainty), and UK class-2 hosiery carries 1.55-fold the reulceration of class-3 over 18 months to 10 years while winning compliance (noncompliance RR 0.69).^[34] The compression resolution: bandage to heal by tolerance, stocking to stay healed by pressure — higher pressure prevents more ulcers and fewer legs tolerate it.^[34][35]

Complications & Pitfalls — the six traps

Set the heat-injury expectation by the flush-laser series: across 405 limbs the success rate is 96.78% with clinically significant heat-induced thrombosis at 2.5% class-3 plus 0.2% class-4, managed on the study rivaroxaban course with complete resolution and zero pulmonary embolism or deep thrombosis observed.^[36]

The healing trap — adding superficial surgery to compression to hasten healing when ESCHAR ties healing at every horizon; operate for recurrence, ablate early for speed.^[9][12] The cutoff trap — reporting 27.4 cm/s or 250 ms as diagnostic thresholds when one hospital cohort owns them; define reflux at 0.5 seconds and label every cutoff with its study.^[3][8] The foam-equivalence trap — offering foam as occlusion-equal when 1-year success trails by 16 points and 14-year reintervention runs seven-fold against laser; consent the repeat-procedure arithmetic.^[17][29] The distal-SSV trap — thermally ablating the distal small saphenous trunk where the sural nerve sits within 5 mm in 90% of legs with fascia shielding in only 15%; the proximal third is the optimal thermal zone.^[38] The MOCA-parity trap — quoting 1-year quality-of-life ties while omitting 47% 5-year occlusion and 23% 7-year proximal reflux; durability, not comfort, separates mechanochemical from thermal.^[27][28] The healed-and-done trap — discharging the healed ulcer without stockings when class-3 cover halves reulceration; the healed leg is a compression leg.^[34]

Prognosis & Disposition — the numbers that set expectations

^{[9] [12] [17] [23] [36] [34]}

Special Populations — contexts that change the emphasis

The small saphenous leg inherits the nerve-first plan: the tibial nerve averages 4.4 mm away at the saphenopopliteal junction and under 1 mm in one-fifth, while the common peroneal nerve averages 14.2 mm — so map the junction, favour the proximal third, and consider non-thermal options where the nerve hugs the trunk.^[38] The ulcer with deep reflux inherits tempered promises: segmental deep disease keeps the ESCHAR recurrence dividend (52 vs 24%) while total deep reflux dissolves it (46 vs 32% ns), and Marston deep insufficiency raises post-ablation recurrence — so quote the stratum, never the average.^[10][32] The large-diameter trunk inherits the recanalisation warning: diameter (OR 1.8) and clinical class (OR 2.1) top the 1-year prediction model across 1226 legs, so consent reintervention before heating a wide trunk.^[39] The pregnant or recently pregnant leg inherits Bonn counselling, not intervention numbers: pregnancies cluster with varicose veins and oedema but not with severe C4–C6 disease — so counsel the risk split and revisit trunk decisions after delivery, since this set holds no intervention numbers for pregnancy.^[5] The high-thrombosis-risk leg inherits the consensus week: any of the seven surveyed factors earns low-molecular-weight heparin with one to two weeks for high-risk patients — consensus cover where trial evidence does not exist.^[37]

Evidence, Guidelines & Regional Differences — the four stories and who led them

The population story is Edinburgh-to-Bonn: Scotland counts prevalence, incidence and progression across 13 years while Bonn splits the risk profiles — shared drivers for bulges and oedema, female protection dissolving at severe disease.^[2][4][5] The ulcer story is ESCHAR-to-EVRA: compression-plus-surgery halves recurrence without hastening healing, then early endovenous ablation within 2 weeks hastens healing and buys ulcer-free time — with 3-year follow-up keeping the cost-effectiveness verdict above 90%.^[9][12][13] The trunk story is REACTIV-to-CLASS-to-Cochrane-to-Helsinki: surgery beats conservative care, laser matches surgery early with kinder recovery, foam trails on occlusion, and the second decade bills foam in reinterventions while quality of life ties throughout.^{[18][15][19][29]} The technique story is thermal-to-tumescent-free: radiofrequency and laser hold occlusion into the nineties at 5 years while mechanochemical slides to the forties, and cyanoacrylate trades peri-procedural satisfaction and no tumescence for hypersensitivity and early-data horizons.^[27][30][31] The stated honesty of this set: no guideline PDF bytes were fetched, so no guideline number appears above — every threshold, timing and technique claim is owned by a trial, Cochrane or cohort abstract instead; regional service patterns vary, so name the trial beside every protocol claim.^[15][35]

Exam Pearls — the one-liners that score

• Burden: one-third of women trunk varices; ulcers 0.3%, history 1%; men 39.7 vs women 32.2% in Edinburgh.^[1][2]
• Reflux: 12.7% at 13 years (0.9%/yr); superficial 8.8%; 0.5-second rule; GSV lower-thigh peak 8.1%.^[3]
• Progression: 57.8% at 4.3%/yr; VV-to-CVI 31.9%; SSV reflux OR 4.73.^[4]
• CEAP-2020: C4c corona, r modifier, segment abbreviations; VCSS 6-to-2, AVVQ 21.4-to-8.8.^[6][7]
• ESCHAR: healing tied 65/65% and 89/93%; recurrence 12/28% and 31/56%; ulcer-free 78/71%.^[9][10]
• EVRA: HR 1.38; 56 vs 82 days; 85.6 vs 76.3%; ICER £3976; 89% at £20k.^[12][14]
• CLASS: foam AVVQ −1.74 vs surgery; complications 1/7/8%; 5-yr laser £3640/QALY.^[15][16]
• Dutch: 88.5/88.2/72.2%; Cochrane laser halves neovascularisation (OR 0.05).^[17][19]
• Long-term: 10-yr groin freedom 73 vs 44%; 14-yr foam reinterventions 56.4%.^[23][29]
• Tributaries: phlebectomy-alone rescues 50%; concomitant RR 0.33.^[25][26]
• Non-thermal: LAMA 91 vs 47%; glue non-inferior at −10%; satisfaction 29.3 vs 25.0.^[27][31][30]
• Staying healed: EU3 RR 0.46; UK2-vs-3 RR 1.55; 4LB-or-hosiery cost-effective.^[34][35]
• Safety: EHIT3-4 2.7%, zero PE/DVT; SSV-SN under 5 mm in 90% distal legs; recanalisation 11% with diameter OR 1.8.^[36][38][39]

13-year reflux 12.7% (0.9%/yr); superficial 8.8, deep 2.6, combined 1.3%; GSV lower-thigh peak 8.1%; baseline superficial reflux multiplies new varicose veins 4.4-fold, combined 7.3-fold (PMID 24951373).^[3] 57.8% progress at 4.3%/yr; 31.9% of VV-only develop CVI; 98% with VV-plus-CVI deteriorate; SSV reflux OR 4.73 and combined deep-plus-superficial OR 2.57 (PMID 26993676).^[4] 37 patients, 43 ulcers under 30 cm2; mean healing 73.6 days; 100% occlusion at 1 week and 3 months; one DVT, no major events (PMID 32205130).^[33] 42 then 47 consultants; >67/>85% good/very-good cutoffs; LMWH for any of 7 risk factors; high-risk 1-2 weeks not a single dose — consensus, never trial evidence (PMID 32611228).^[37] Assemble the cost ladder honestly: EVLA dominates surgery at 5 years in CLASS, early ablation is 89-92% cost-effective in EVRA, RFA beats stripping at 1 year — different horizons, same direction (PMIDs 25274220, 30741425, 38311050).^[13]

References40ShowHide

1. [1]Fowkes FG, et al. Prevalence and risk factors of chronic venous insufficiency. Angiology, 2001.PMID 11510598
2. [2]Lee AJ, et al. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol, 2003.PMID 12654412
3. [3]Robertson LA, et al. Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study. Eur J Vasc Endovasc Surg, 2014.PMID 24951373
4. [4]Lee AJ, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord, 2015.PMID 26993676
5. [5]Kraus AL, et al. Differences in risk profile associated with varicose veins and chronic venous insufficiency - results from the Bonn Vein Study 1. Vasa, 2024.PMID 38426384
6. [6]Lurie F, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord, 2020.PMID 32113854
7. [7]Lattimer CR, et al. Responsiveness of individual questions from the venous clinical severity score and the Aberdeen varicose vein questionnaire. Phlebology, 2014.PMID 23180751
8. [8]Singh AK, et al. Quantification of Superficial Venous Reflux by Duplex Ultrasound - Role of Peak Reflux Velocity and Reflux Time in the Assessment of Varicose Vein. J Nepal Health Res Counc, 2020.PMID 33210638
9. [9]Barwell JR, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet, 2004.PMID 15183623
10. [10]Gohel MS, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ, 2007.PMID 17545185
11. [11]Gohel MS, et al. Randomized clinical trial of compression plus surgery versus compression alone in chronic venous ulceration (ESCHAR study)--haemodynamic and anatomical changes. Br J Surg, 2005.PMID 15584055
12. [12]Gohel MS, et al. A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. N Engl J Med, 2018.PMID 29688123
13. [13]Gohel MS, et al. Long-term Clinical and Cost-effectiveness of Early Endovenous Ablation in Venous Ulceration: A Randomized Clinical Trial. JAMA Surg, 2020.PMID 32965493
14. [14]Epstein DM, et al. Cost-effectiveness analysis of a randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration. Br J Surg, 2019.PMID 30741425
15. [15]Brittenden J, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technol Assess, 2015.PMID 25858333
16. [16]Tassie E, et al. Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. Br J Surg, 2014.PMID 25274220
17. [17]Biemans AA, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. J Vasc Surg, 2013.PMID 23769603
18. [18]Michaels JA, et al. Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). Health Technol Assess, 2006.PMID 16707070
19. [19]Nesbitt C, et al. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices. Cochrane Database Syst Rev, 2014.PMID 25075589
20. [20]Carradice D, et al. Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg, 2011.PMID 21283981
21. [21]Darwood RJ, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg, 2008.PMID 18278775
22. [22]Pronk P, et al. Randomised controlled trial comparing sapheno-femoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anaesthesia: one year results. Eur J Vasc Endovasc Surg, 2010.PMID 20888274
23. [23]Eggen CAM, et al. Ten-year follow-up of a randomized controlled trial comparing saphenofemoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anesthesia. J Vasc Surg Venous Lymphat Disord, 2022.PMID 34450354
24. [24]Flessenkämper I, et al. Endovenous laser ablation with and without high ligation compared to high ligation and stripping for treatment of great saphenous varicose veins: Results of a multicentre randomised controlled trial with up to 6 years follow-up. Phlebology, 2016.PMID 25342648
25. [25]Biemans AA, et al. The effect of single phlebectomies of a large varicose tributary on great saphenous vein reflux. J Vasc Surg Venous Lymphat Disord, 2014.PMID 26993185
26. [26]Xie Y, et al. Combined endovenous ablation with phlebectomy or foam sclerotherapy versus endovenous ablation alone for lower limb varicose veins: A systematic review and meta-analysis. Phlebology, 2026.PMID 41990331
27. [27]Lim AJM, et al. Editor's Choice - Five Year Follow Up of a Randomised Clinical Trial of Endovenous Laser Ablation versus Mechanochemical Ablation for Superficial Venous Incompetence (LAMA trial). Eur J Vasc Endovasc Surg, 2025.PMID 40288564
28. [28]Hurmerinta-Kurkijärvi OL, et al. Randomised Trial of Mechanochemical or Thermal Ablation for Great Saphenous Vein Insufficiency: 7 Year Follow Up. Eur J Vasc Endovasc Surg, 2026.PMID 42401285
29. [29]Rahman T, et al. Fourteen Year Outcomes of a Randomised Controlled Trial Comparing Endovenous Laser Ablation, High Ligation and Stripping, and Ultrasound Guided Foam Sclerotherapy for Great Saphenous Varicose Veins. Eur J Vasc Endovasc Surg, 2026.PMID 41633433
30. [30]Gohel M, et al. Randomised Clinical Trials Comparing Cyanoacrylate Closure with Surgical Stripping and Endovenous Thermal Ablation for Chronic Venous Disease. Eur J Vasc Endovasc Surg, 2026.PMID 42203167
31. [31]Zhi K, et al. Glue ablation therapy for patients with great saphenous vein varicosities: A randomized, parallel-controlled, multicenter, non-inferiority trial. J Transl Int Med, 2025.PMID 41438465
32. [32]Marston WA, et al. Incidence of venous leg ulcer healing and recurrence after treatment with endovenous laser ablation. J Vasc Surg Venous Lymphat Disord, 2017.PMID 28623990
33. [33]Chan SSJ, et al. The utility of endovenous cyanoacrylate glue ablation for incompetent saphenous veins in the setting of venous leg ulcers. J Vasc Surg Venous Lymphat Disord, 2020.PMID 32205130
34. [34]de Moraes Silva MA, et al. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev, 2024.PMID 38451842
35. [35]Phung H, et al. Compression systems for venous leg ulcers: a network meta-analysis and cost-effectiveness analysis. EClinicalMedicine, 2026.PMID 42518940
36. [36]Burta MC, et al. Assessing Endovenous Heat-Induced Thrombosis in Flush Endovenous Laser Ablation: A Study on Incidence, Risk Factors, and Patient Outcomes. J Clin Med, 2025.PMID 40943923
37. [37]Dattani N, et al. Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study. Phlebology, 2020.PMID 32611228
38. [38]Kerver AL, et al. The surgical anatomy of the small saphenous vein and adjacent nerves in relation to endovenous thermal ablation. J Vasc Surg, 2012.PMID 22503186
39. [39]Van der Velden SK, et al. Predictors of Recanalization of the Great Saphenous Vein in Randomized Controlled Trials 1 Year After Endovenous Thermal Ablation. Eur J Vasc Endovasc Surg, 2016.PMID 26994834
40. [40]Nelzén O, et al. Editor's Choice - Short Term Cost Effectiveness of Radiofrequency Ablation and High Ligation and Stripping for Great Saphenous Vein Incompetence. Eur J Vasc Endovasc Surg, 2024.PMID 38311050